Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus

Lupus

Volumn 16, Issue 5, 2007, Pages 350-354

  Kuruma, Katia Akemi M ^a   Borba, E F ^a   Lopes, M H ^a   De Carvalho, J F ^a   Bonfa E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Efficacy; Hepatitis B; Safety; Systemic lupus erythematosus; Vaccine

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LABORATORY TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEROCONVERSION; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DRUG TOXICITY; FEMALE; HEPATITIS B VACCINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

EID: 34447504897     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307078225     Document Type: Article

References (49)

1. World Health Organization. Hepatitis B vaccines. Weekly epidemiological record 2004; 79: 255-263. www.who.int/immunization/ wer7928HepB July04positionpaper.pdf
2. Maillefert JF, Sibilia J, Toussirot E et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999; 38: 978-983.
3. Maillefert JF, Tavernier C, Sibilia J, Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al. and the letter by Senecal et al. Arthritis Rheum 2000; 43: 468-469 (Letter).
4. Di Giusto CA, Bernhard JD. Erythema nodosum provoked by hepatitis B vaccine. Lancet 1986; 2: 1042.
5. Goolsby PL. Erythema nodosum after Recombivax HB hepatitis B vaccine. N Engl J Med 1989; 26: 1198-1199.
6. McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long term follow-up. Hepatology 1989; 9: 97-101.
7. Zaas A, Scheel P, Venbrux A, Hellmann DB. Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. J Rheumatol 2001; 28: 1116-1120.
8. Le Hello C, Cohen P, Bousser MG, Letellier P, Guillevin L. Suspected hepatitis B vaccination related vasculitis. J Rheumatol 1999; 26: 191-194.
9. Begier EM, Langford CA, Sneller MC, Wise RP, Ball R; VAERS Working Group. Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol 2004; 31: 2181-2188.
10. Trevisani F, Gattinara GC, Caraceni P et al. Transverse myelitis following hepatitis B vaccination. J Hepatol 1993; 19: 317-318.
11. Fried M, Conen D, Conzelmann M, Steinemann E. Uveitis after hepatitis B vaccination. Lancet 1987; 2: 631-632.
12. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet 1994; 344: 1293 (Letter).
13. Meyboom RHB, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines. Lancet 1995; 345: 1638 (Letter).
14. Neau D, Bonnet F, Michaud M et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis 1998; 30: 115-118.
15. Finielz P, Lam Kam Sang LF, Guserix J. Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant 1998; 13: 2420-2421.
16. Martinez E, Domingo P. Evans's syndrome triggered by recombinant hepatitis B vaccine. Clin Infect Dis 1992; 15: 1051.
17. Vautier G, Carty JE. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination. Br J Rheumatol 1994; 33: 991.
18. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998; 25: 1687-1693.
19. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. Nephron 1992; 62: 236.
20. Mamoux V, Dumont C. Lupus erythematosus disseminatus and vaccination against hepatitis B virus. Arch Pediatr 1994; 1: 307-308.
21. Guiserix J. Systemic lupus erythematosus following hepatitis B vaccine. Nephron 1996; 74: 441.
22. Grezard P, Chefai M, Philippot V, Perrot H, Faisant M. Ann Dermatol Venereol 1996; 123: 657-659.
23. Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. Major adverse reaction to yeast-derived hepatitis B vaccines - a review. Vaccine 1998; 16: 329-334.
24. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001; 10: 237-240.
25. Ioannou Y, Isenberg DA. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus 1999; 8: 497-501.
26. Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS. Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol 1989; 142: 1482-1486.
27. Moens U, Seternes OM, Hey AW et al. In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones. Proc Natl Acad Sci USA 1995; 92: 12393-12397.
28. Rai G, Ray S, Shaw RE et al. Models of systemic lupus erythematosus: development of autoimmunity following peptide immunizations of non-inbred pedigreed rabbits. J Immunol 2006; 176: 660-667.
29. Lilic D, Ghosh SK. Liver dysfunction and DNA antibodies after hepatitis B vaccination. Lancet 1994; 344: 1292-1293.
30. Senécal JL, Bertrand C. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al. Arthritis Rheum 1999; 42: 1307-1308 (Letter).
31. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002; 55: 982-989.
32. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006; 15: 778-783.
33. Williams GW, Steinberg AD, Reinertsen JL et al. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med 1978; 88: 729-734.
34. Abu-Shakra M, Press J, Varsano N et al. Specific antibody response after influenza immunization in SLE. J Rheumatol 2002; 29: 2555-2557.
35. Holvast A, Huckriede A, Wilschut J et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-918.
36. Del Porto F, Lagana B, Biselli R et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24: 3217-3223.
37. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-1834.
38. Klippel JH, Karsh J, Stahl NI et al. Controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1321-1325.
39. Elkayam O, Paran D, Caspi D et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infec Dis 2002; 34: 147-153.
40. Mercado U. Antibody responses following vaccination in lupus patients. Rev Invest Clin 2003; 55: 93-94 (Letter).
41. Tan EM, Cohen AS, Fries JF et al. The revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
42. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
43. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
44. Isenberg DA, Maddison PJ. Detection of antibodies to double stranded DNA and extractable nuclear antigen. J Clin Pathol 1987; 40: 1374-1381.
45. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
46. Looney RJ, Hasan MS, Coffin D et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001; 21: 30-36.
47. Louie JS, Nies KM, Shoji KT et al. Clinical and Antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88: 790-792.
48. CDC (Center for Disease Control and Prevention). Hepatitis B. In Atkinson W, Hamborsky J, Wolfe C eds. Epidemiology and prevention of vaccine-preventable diseases, 9th edition. Washington, DC: Public Healthy Foundation, 2006: 207-231.
49. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002; 21: 369-372.